Skip to main content
Top
Published in: Tumor Biology 7/2014

01-07-2014 | Editorial

Letter regarding Wang et al. entitled “Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systematic review and meta-analysis”

Authors: Nerea Bilbao-Aldaiturriaga, Idoia Martin-Guerrero, Africa Garcia-Orad

Published in: Tumor Biology | Issue 7/2014

Login to get access

Excerpt

We have read with interest the article by Wang et al. [1] in a recent issue of Tumor Biology. In this study, the authors conducted a systematic review and meta-analysis to assess the effects of two murine double minute 2 (MDM2) polymorphisms, rs2274799 and rs160916, on the risk and survival of osteosarcoma. The authors concluded that MDM2 polymorphisms had effects on the risk but had no effect on the survival of patients with osteosarcoma. In a recent letter to the editor, Liu et al. [2] detected several weaknesses in the meta-analysis. Firstly, they criticize the small number of papers included in the analyses, which could lead to false significant associations. They also point out the lack of information in the methods used to select the studies. Moreover, they comment the absence of Hardy-Weinberg equilibrium analysis in the control population. Finally, they question the quality of the selected studies. In the present letter, we would like to add some other inaccuracies found in the Wang et al. [1] meta-analysis. …
Literature
1.
go back to reference Wang L, Liu Z, Jing P, Shao L, Chen L, He X, Gong W: Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol 2013 Wang L, Liu Z, Jing P, Shao L, Chen L, He X, Gong W: Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systemic review and meta-analysis. Tumour Biol 2013
2.
go back to reference Liu G, Xu W, Hao Y, Xu Z: Letter regarding Wang et al. Entitled “Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: A systemic review and meta-analysis”. Tumour Biol 2013 Liu G, Xu W, Hao Y, Xu Z: Letter regarding Wang et al. Entitled “Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: A systemic review and meta-analysis”. Tumour Biol 2013
3.
go back to reference Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both snp309 and mdm2 amplification in sarcomagenesis. Clin Cancer Res. 2011;17:416–26.CrossRefPubMed Ito M, Barys L, O'Reilly T, Young S, Gorbatcheva B, Monahan J, et al. Comprehensive mapping of p53 pathway alterations reveals an apparent role for both snp309 and mdm2 amplification in sarcomagenesis. Clin Cancer Res. 2011;17:416–26.CrossRefPubMed
4.
go back to reference Naumov VA, Generozov EV, Solovyov YN, Aliev MD, Kushlinsky NE. Association of fgfr3 and mdm2 gene nucleotide polymorphisms with bone tumors. Bull Exp Biol Med. 2012;153:869–73.CrossRefPubMed Naumov VA, Generozov EV, Solovyov YN, Aliev MD, Kushlinsky NE. Association of fgfr3 and mdm2 gene nucleotide polymorphisms with bone tumors. Bull Exp Biol Med. 2012;153:869–73.CrossRefPubMed
Metadata
Title
Letter regarding Wang et al. entitled “Effects of murine double minute 2 polymorphisms on the risk and survival of osteosarcoma: a systematic review and meta-analysis”
Authors
Nerea Bilbao-Aldaiturriaga
Idoia Martin-Guerrero
Africa Garcia-Orad
Publication date
01-07-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 7/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-1882-4

Other articles of this Issue 7/2014

Tumor Biology 7/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine